Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia

Drugs of Today

Volumn 44, Issue 12, 2008, Pages 887-893

  Owen, Richard T ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DEBRISOQUINE; DEXTROMETHORPHAN; FLUVOXAMINE; OMEPRAZOLE; PHENYTOIN; PLACEBO; PROPRANOLOL; THEOPHYLLINE; TIZANIDINE; WARFARIN;

ANOREXIA; ANORGASMIA; ANXIETY; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULARY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION DISORDER; HEADACHE; HUMAN; INSOMNIA; LIBIDO; NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOCIAL PHOBIA; SOMNOLENCE; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; VOMITING; WEIGHT GAIN; YAWNING;

CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PHOBIC DISORDERS;

EID: 61949279860     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.12.1299291     Document Type: Review

References (19)

1. Kessler, B.C., Chiu, W.T., Demler, O., Walters, E.E. Prevalence, severity and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005, 62(6): 617-27.
2. National Institute of Mental Health. The Numbers Count: Mental Disorders In America. Available at: http://www.nimh.nih.gov/health/ publications/the-numbers-cout-mental-disorders-in-america.shtml. Accessed September 24, 2008.
3. Ballenger, J.C., Davidson, J.R.T., Lecrubier, Y. et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Int Clin Psychopharmacol 1998, 59(Suppl.): 54-60.
4. Clinical Practice Guidelines. Management of Anxiety Disorders. 5. Social Anxiety Disorder. Can J Psychiatry 2006, 5 (Suppl. 2): 35s-42s.
5. Koran, L.M. et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007, 164(Suppl.): 1-56
6. Jazz Pharmaceuticals. U.S. prescribing information for LUVOX CR®. Available at: http://www.luvoxcr.com. Accessed September 24, 2008.
7. Hyttel, J. Comparative pharmacology of specific serotonin reuptake inhibitors. Nord J Psychiatry 1993, 47(530): 5-12
8. Stahl, S.M. Antidepressant treatment of psychotic depression: Potential role of sigma receptor. CNS Spectr 2005, 10(4): 319-23.
9. Hollander, E., Koran, L.M., Goodman, W.K. et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003, 64(6): 640-7.
10. Westenberg, H.G.M., Stein, D.J., Yang, H., Liu, D., Barbato, L.M. A double-blind, placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004, 24(1): 49-55.
11. Davidson, J., Yaryura-Tobias, J., DuPont, R. et al. Fluvoxamine controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004, 24(2): 118-25.
12. Stein, D.J., Westenberg, H.G., Yang, H., Li, D., Barbato, L.M. Fluvoxamine CR in the long-term treatment of social anxiety disorder: The 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003, 6(4): 317-23.
13. Goodman, W.K., Kozak, M.J., Liebowitz, M., White, K. L. Treatment of obsessive-compulsive disorder with fluvoxamine: A multicenter, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996, 11(1): 21-9.
14. Greist, J.H., Jenike, M.A., Robinson, D., Rasmussen, S.A. Efficacy of fluvoxamine in obsessive-compulsive disorder: Results of a multicenter, double-blind, placebo-controlled trial. Eur J Clin Res 1995, 7: 195-204.
15. Stein, M.B., Fyer, A.J., Davidson, J.R.T., Pollack, M.H., Wiita, B. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study. Am J Psychiatry 1999, 156(5): 756-60.
16. van Vliet, I.M., den Boer, J.A., Westenberg, H.G.M. Psychopharmacological treatment of social phobia: A double-blind, placebo-controlled study with fluvoxamine. Psychopharmacology 1994, 115: 128-34.
17. Oliver, B., Gommans, J., Gugten, J.V. et al. Stimulus properties of the selective 5-HT reuptake inhibitor fluvoxamine in conditioned taste aversion procedures. Pharmacol Biochem Behav 1999, 64(2): 213-20.
18. Bogetto, F., Albert, H., Maina, G. Sertraline treatment of obsessive-complulsive disorder: Efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 2002, 12(3): 181-6.
19. Koran, L.M., Sallee, F.R., Pallanti, S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997, 154(3): 396-401.